US SEC Trading Suspension Halt Orders — August 31, 2026

Received a 180-day cure period (to ~Feb 2027) to regain $1.00 bid compliance; stock continues trading with a non-compliance indicator. If the company executes a reverse split or operational catalyst, the stock could re-rate.

Successfully resolved a Nasdaq public float deficiency within one week (Aug 14 to Aug 21, 2026); no further action required. Demonstrates effective corporate governance and proactive compliance.

Filed an appeal hearing request on Aug 28, 2026, within the 7-day window; shares continue trading pending the hearing. The company has a near-term catalyst to potentially reverse the delisting.

Trading has been suspended since March 27, 2026 (over 5 months), and the Nasdaq Listing Council affirmed delisting on Aug 25, 2026. The stock will move to OTC Expert Market, implying near-zero liquidity.

No insider buying or capital allocation actions disclosed; the company's silence on a remediation plan raises uncertainty about the cure outcome.

Auditor resignation (LAO Professionals) in June 2026 and appointment of a new auditor (TQ International) for delayed FY2025 audits signal governance and reporting risks.

The Nasdaq board retains discretion to review the Listing Council's decision under Rule 5825, but no such review has been called. The lack of board intervention is a negative signal.

The stock is trading below $1.00 with no disclosed reverse split or capital infusion plan; failure to cure within 180 days leads to automatic delisting.

The reverse split (1-for-4) that caused the float deficiency could deter retail investors and signals a low stock price.

The Nasdaq Listing Council affirmed delisting on Aug 25, 2026; trading has been suspended since March 27, 2026. Shares will move to OTC Expert Market with minimal liquidity.

The hearing request is filed, but no date is set. If the appeal fails, the stock will be delisted from NYSE American.

The stock's average closing bid price was below $1.00 for 30 consecutive days as of Aug 26, 2026. Without a cure (reverse split or price recovery), delisting is likely.

LAO Professionals resigned on June 8, 2026, and TQ International was appointed on Aug 26, 2026. The delayed FY2025 audit and interim reviews create reporting uncertainty.

The 1-for-4 reverse split that triggered the float deficiency may indicate a low stock price and potential future bid price compliance issues.

No dividends, buybacks, or insider transactions disclosed; the company appears financially constrained.

The filing contains no forward-looking statements, guidance, or capital allocation plans, leaving investors without a roadmap.

The combination of a delisting notice and a recent auditor resignation suggests potential internal control weaknesses.

No insider trading activity was reported in any of the four filings, indicating a lack of management conviction or an inability to trade due to blackout periods.

The 180-day cure period (ending ~Feb 2027) provides a binary event. If Microvast announces a reverse split or a business milestone, the stock could experience a sharp rally.

Nasdaq closed the review with no further action, removing a key overhang. The stock may attract investors seeking de-risked small-cap plays.

The upcoming oral hearing (date TBD) is a near-term event that could reverse the delisting if the company presents a credible compliance plan.

For distressed-debt or special-situation investors, the OTC move may create a mispricing if the company's fundamentals are stronger than implied by the delisting.

Among the three companies facing delisting, Microvast has the longest cure period (180 days) and the most time to execute a turnaround, offering the highest optionality.

The company's swift compliance (within 7 days) suggests strong management execution, which could be a positive signal for future operational performance.

TQ International's appointment to audit FY2025 and interim periods may restore financial reporting credibility if completed on time.

Historical data shows that some micro-cap stocks rebound after OTC listing if they regain compliance; investors with high risk tolerance could monitor Cambium and Northann for such reversals.

Three out of four filings involve delisting or deficiency notices (Northann, Cambium, Microvast), indicating a cluster of small-cap companies failing to meet exchange listing standards. This suggests tightening regulatory enforcement or sector-wide financial distress.

Northann Corp.'s auditor resignation (June 2026) and subsequent replacement (Aug 2026) highlight a pattern where auditor changes often precede or accompany delisting risks. Investors should monitor auditor stability in micro-caps.

Profusa's reverse split (1-for-4) triggered a public float deficiency, while Microvast may need a reverse split to cure its bid price issue. Reverse splits can solve compliance but often signal underlying weakness.

None of the four filings reported insider transactions, pledges, or holdings changes. In distressed micro-caps, the absence of insider buying may indicate low management confidence or restricted trading windows.

Cambium Networks' move to OTC Expert Market (from Nasdaq) exemplifies the liquidity collapse that follows delisting, with no market makers and minimal trading volume. This pattern is a key risk for investors holding through delisting.

The oral hearing date (TBD) is a critical catalyst. If the appeal succeeds, the stock avoids delisting; if it fails, the stock will be suspended. Monitor for hearing scheduling and outcome.

The 180-day cure period runs through ~Feb 2027. Watch for any announcement of a reverse split, capital raise, or operational milestone that could lift the stock above $1.00.

Under Rule 5825, the Nasdaq board may still call the Listing Council's decision for review. Any such action would be a surprise positive catalyst.

After the public float issue, monitor for any subsequent bid price or market value deficiencies. The reverse split may have weakened the stock's price floor.

TQ International must audit FY2025 and interim periods (March 31, 2026 and June 30, 2026). Delays in filing audited financials could trigger additional regulatory issues.

Any insider buying in the coming weeks would be a strong signal of management confidence in the cure plan.

Watch for additional deficiency notices (e.g., market value of public float, stockholders' equity) that could compound existing delisting risks.